Sitagliptin / Metformin hydrochloride Mylan Europäische Union - Schwedisch - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Dimethyl fumarate Mylan Europäische Union - Schwedisch - EMA (European Medicines Agency)

dimethyl fumarate mylan

mylan ireland limited - dimetylfumarat - multipel skleros, skovvis förlöpande - immunsuppressiva - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Pirfenidone Viatris Europäische Union - Schwedisch - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - pirfenidon - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunsuppressiva - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Dapagliflozin Viatris Europäische Union - Schwedisch - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - läkemedel som används vid diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 och 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Ciprofloxacin Hospira 2 mg/ml Infusionsvätska, lösning Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

ciprofloxacin hospira 2 mg/ml infusionsvätska, lösning

hospira uk limited - ciprofloxacinlaktat - infusionsvätska, lösning - 2 mg/ml - glukosmonohydrat hjälpämne; ciprofloxacinlaktat 2,54 mg aktiv substans - ciprofloxacin

Gemcitabine Accord 1 g Pulver till infusionsvätska, lösning Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

gemcitabine accord 1 g pulver till infusionsvätska, lösning

accord healthcare b.v. - gemcitabinhydroklorid - pulver till infusionsvätska, lösning - 1 g - gemcitabinhydroklorid 1138,5 mg aktiv substans; mannitol hjälpämne - gemcitabin

Gemcitabine Accord 2 g Pulver till infusionsvätska, lösning Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

gemcitabine accord 2 g pulver till infusionsvätska, lösning

accord healthcare b.v. - gemcitabinhydroklorid - pulver till infusionsvätska, lösning - 2 g - mannitol hjälpämne; gemcitabinhydroklorid 2280 mg aktiv substans - gemcitabin

Gemcitabine Accord 200 mg Pulver till infusionsvätska, lösning Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

gemcitabine accord 200 mg pulver till infusionsvätska, lösning

accord healthcare b.v. - gemcitabinhydroklorid - pulver till infusionsvätska, lösning - 200 mg - gemcitabinhydroklorid 227,7 mg aktiv substans; mannitol hjälpämne - gemcitabin

Metotrexat Accord 100 mg/ml Koncentrat till infusionsvätska, lösning Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

metotrexat accord 100 mg/ml koncentrat till infusionsvätska, lösning

accord healthcare b.v. - metotrexat - koncentrat till infusionsvätska, lösning - 100 mg/ml - metotrexat 100 mg aktiv substans - metotrexat

Metotrexat Accord 25 mg/ml Injektionsvätska, lösning Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

metotrexat accord 25 mg/ml injektionsvätska, lösning

accord healthcare b.v. - metotrexat - injektionsvätska, lösning - 25 mg/ml - metotrexat 25 mg aktiv substans - metotrexat